DNA vs STEM โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
DNA Captures Institutional Edge (2โ1 Pillars ยท 5โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Ginkgo Bioworks Holdings, Inc. (DNA) driven by superior Momentum & Technical, Options & Structure while STEM counters with relative strength in Growth & Margin. Fundamentally, DNA trades at N/M Forward P/E with -202.5% operating margin (-5.7% YoY revenue) versus STEM at N/M Forward P/E and -12.1% operating margin (-4.1% YoY). In options structure, DNA sits in BREAKDOWN (22nd %ile IV; Dealer Gamma Walls on Pro) against STEM sits in BREAKDOWN (39th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | DNA Revenue | STEM Revenue | DNA Op. Margin | STEM Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | $50M | $20M | -132.1% | -272.6% | DNA |
| FY2020 | $80M | $40M | -178.8% | -136.0% | STEM |
| FY2021 | $310M | $130M | -582.6% | -65.2% | STEM |
| FY2022 | $480M | $360M | -462.4% | -36.1% | STEM |
| FY2023 | $250M | $460M | -343.8% | -38.9% | STEM |
| FY2024 | $230M | $140M | -246.5% | -580.6% | DNA |
| FY2025 | $170M | $160M | -185.3% | -35.6% | STEM |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | DNA | STEM | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $531.5M | $7.1M | Larger Scale | DNA |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -5.7% | -4.1% | Higher Growth | STEM |
| Operating Margin (TTM) Profitability | -202.5% | -12.1% | Higher Margin | STEM |
| Net Profit Margin Profitability | -192.0% | -43.6% | Higher Margin | STEM |
| Return on Equity (ROE) Capital Efficiency | -58.2% | -5920.8% | Higher ROE | DNA |
| 52-Week Range Position Momentum | 16% ($5โ$18) | 0% ($1โ$22) | Stronger Trend | DNA |
| Beta / 30D Volatility Risk Regime | 3.12ฮฒ ยท 152% Vol | 4.60ฮฒ ยท 234% Vol | Lower Realized Risk | DNA |
| Unified Institutional Score Composite Signal | 52.1 / 100 (HOLD) | 42.4 / 100 (HOLD) | Higher Composite | DNA |